MHLW Approves Sandoz's Somatropin As First Biosimilar Product In Japan
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Japan's Ministry of Health, Labor and Welfare has approved Sandoz's recombinant human growth hormone somatropin injection, marking it the first biosimilar product approved in Japan, a MHLW Pharmaceutical Examination Division official confirmed June 26
You may also be interested in...
Sandoz Launches Japan's First Biosimilar; Sees Huge Market Potential In Japan
Novartis's generic subsidiary Sandoz launched recombinant human growth hormone somatropin in Japan. Approved in June with the same indications as Pfizer's Genotropin (somatropin), Sandoz's somatropin marks the first biosimilar launch and the company looks to further generic launches in Japan
Sandoz Launches Japan's First Biosimilar; Sees Huge Market Potential In Japan
Novartis's generic subsidiary Sandoz launched recombinant human growth hormone somatropin in Japan. Approved in June with the same indications as Pfizer's Genotropin (somatropin), Sandoz's somatropin marks the first biosimilar launch and the company looks to further generic launches in Japan
Sandoz Launches Japan's First Biosimilar; Sees Huge Market Potential In Japan
The company plans to launch six to seven new products by the end of the year, and 10 additional products in 2010.